New Methodological Approaches to Assess Value of Immuno-Oncology Therapies

Published May 24, 2017
Boston, MA—MAY 24, 2017—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosted a morning session at its 22nd Annual International Meeting in Boston, MA, USA that examined cost-effectiveness models for innovative oncology treatments. The session, Cost-Effectiveness Models for Innovative Oncology Treatments: How Different Methodological Approaches Can Be Used to Estimate the Value of Novel Therapies [IP17], was moderated by Nicholas Latimer, MSc, PhD, Senior Research Fellow, ScHARR, University of Sheffield, Sheffield, UK. Panelists included:
  • Scott D. Ramsey, MD, PhD, Full Member, HICOR, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Andrew Briggs, DPhil, MSc, Visiting Investigator, Center for Health Policy and Outcomes, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
The emergence of novel immuno-oncology therapies have triggered an evolution of cost-effectiveness models so that these models might better capture efficacy and address uncertainty. These new methodological approaches must overcome several challenges, including dealing with short follow-up times, addressing immature data, and resolving the uncertainly of how extrapolation should be performed. Nicholas Latimer, MSc, PhD facilitated a debate on the issues with the panelists. Scott D. Ramsey, MD, PhD presented a mixed model approach intended to capture the value of these novel therapies. Andrew Briggs, DPhil, MSc presented an alternative method using response-based modeling for assessing the value of immuno-oncology therapies. Additional information on the ISPOR 22nd Annual International Meeting can be found here. Released presentations from the conference can be found here. Interested parties can follow news at ISPOR’s press site and on social media using the conference hashtag #ISPORBoston.

###

  ABOUT ISPOR The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

ISPOR Publishes Insights From Its First Global HTA Roundtable

Apr 21, 2025

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) published the insights from its first Global Health Technology Assessment (HTA) Roundtable in an article in the March/April issue of Value & Outcomes Spotlight.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×